Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.
Mesalamine has been the first-line of therapy in patients with inflammatory bowel disease (IBD) since the 1960s. This article serves as a review of the different 5-aminosalicylic acid compounds, release formulations, use and dosing in the treatment of IBD, in particular ulcerative colitis.
University of Pennsylvania School of Medicine, Suite 100, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104, USA.
Irene
I
Sonu
Ming Valerie
MV
Lin
Wojciech
W
Blonski
Gary R
GR
Lichtenstein
D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D000636:Aminosalicylic Acids